[go: up one dir, main page]

AU2002211662A1 - Nf-kappab inhibitors - Google Patents

Nf-kappab inhibitors

Info

Publication number
AU2002211662A1
AU2002211662A1 AU2002211662A AU1166202A AU2002211662A1 AU 2002211662 A1 AU2002211662 A1 AU 2002211662A1 AU 2002211662 A AU2002211662 A AU 2002211662A AU 1166202 A AU1166202 A AU 1166202A AU 2002211662 A1 AU2002211662 A1 AU 2002211662A1
Authority
AU
Australia
Prior art keywords
kappab inhibitors
kappab
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211662A
Inventor
James F. Callahan
Amy K. Roshak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002211662A1 publication Critical patent/AU2002211662A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002211662A 2000-10-12 2001-10-12 Nf-kappab inhibitors Abandoned AU2002211662A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23976000P 2000-10-12 2000-10-12
US60239760 2000-10-12
PCT/US2001/031865 WO2002030423A1 (en) 2000-10-12 2001-10-12 NF-λB INHIBITORS

Publications (1)

Publication Number Publication Date
AU2002211662A1 true AU2002211662A1 (en) 2002-04-22

Family

ID=22903605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211662A Abandoned AU2002211662A1 (en) 2000-10-12 2001-10-12 Nf-kappab inhibitors

Country Status (4)

Country Link
EP (1) EP1328272A1 (en)
JP (1) JP2004532797A (en)
AU (1) AU2002211662A1 (en)
WO (1) WO2002030423A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366114A1 (en) 2000-10-26 2005-01-24 Tularik Inc. Antiinflammation agents
WO2003041640A2 (en) * 2001-11-09 2003-05-22 The General Hospital Corporation METHODS FOR TREATING ISCHEMIC REPERFUSION INJURY USING IkB KINASE-BETA INHIBITORS
AU2002365611A1 (en) 2001-12-05 2003-06-17 F. Hoffmann - La Roche Ag Inflammation modulators
US7528161B2 (en) 2002-05-31 2009-05-05 Michigan State University NF-kappaB inhibitors and uses thereof
US6878735B2 (en) * 2002-05-31 2005-04-12 Board Of Trustees Of Michigan State University Multi-substituted imidazolines and method of use thereof
US7345078B2 (en) * 2002-05-31 2008-03-18 The Board Of Trustees Of Michigan State University NF-κB inhibitors and uses thereof
CA2502429A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
PE20060748A1 (en) 2004-09-21 2006-10-01 Smithkline Beecham Corp INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2
UA99699C2 (en) 2005-06-30 2012-09-25 Смитклайн Бичам Корпорейшн Indole carboxamide derivatives and pharmaceutical composition comprising thereof
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
PE20081889A1 (en) 2007-03-23 2009-03-05 Smithkline Beecham Corp INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
BRPI0910850B1 (en) 2008-04-21 2022-06-14 Otonomy, Inc. INTRATYMPANIC COMPOSITION INCLUDING BRAIN-DERIVED NEUROTROPHIC GROWTH FACTOR (BDNF) FOR THE TREATMENT OR PREVENTION OF HEARING LOSS
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8299055B2 (en) 2008-10-02 2012-10-30 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and the use thereof
JP2012520257A (en) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Indole derivatives as IKK2 inhibitors
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319840A (en) * 1970-08-27 1973-06-13 Beecham Group Ltd Substituted 5-amino imidazoles
US6369235B1 (en) * 1997-02-25 2002-04-09 The United States Of America As Represented By The Department Of Health And Human Services Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection

Also Published As

Publication number Publication date
JP2004532797A (en) 2004-10-28
WO2002030423A1 (en) 2002-04-18
EP1328272A1 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001237041A1 (en) Kinase inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
AU2003300832A1 (en) NF-KappaB INHIBITORS
AU4882101A (en) Mmp-12 inhibitors
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2001234088A1 (en) TNF-alpha inhibitors
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001294557A1 (en) Thrombin inhibitors
AU5248800A (en) Fading inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2002222627A1 (en) Tak1 inhibitors
AU2001255090A1 (en) Cdk inhibitors having 3-hydroxychromen-4-one structure
GB0030284D0 (en) Enzyme inhibitors
AU3235100A (en) Prothease inhibitors
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU2003224941A1 (en) NF-KappaB INHIBITORS